Abpro Holdings, Inc. (ABP) - Total Assets
Based on the latest financial reports, Abpro Holdings, Inc. (ABP) holds total assets worth $1.70 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See ABP total equity for net asset value and shareholders' equity analysis.
Abpro Holdings, Inc. - Total Assets Trend (2016–2024)
This chart illustrates how Abpro Holdings, Inc.'s total assets have evolved over time, based on quarterly financial data.
Abpro Holdings, Inc. - Asset Composition Analysis
Current Asset Composition (December 2024)
Abpro Holdings, Inc.'s total assets of $1.70 Million consist of 81.0% current assets and 19.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 61.2% |
| Accounts Receivable | $323.00K | 6.9% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $364.00K | 7.8% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2016–2024)
This chart illustrates how Abpro Holdings, Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Abpro Holdings, Inc. stock valuation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Abpro Holdings, Inc.'s current assets represent 81.0% of total assets in 2024, a decrease from 94.4% in 2016.
- Cash Position: Cash and equivalents constituted 61.2% of total assets in 2024, down from 92.0% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 7.0% of total assets, an increase from 0.0% in 2016.
- Asset Diversification: The largest asset category is intangible assets at 7.8% of total assets.
Abpro Holdings, Inc. Competitors by Total Assets
Key competitors of Abpro Holdings, Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Royalty Pharma Plc
NASDAQ:RPRX
|
USA | $19.62 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
|
China | CN¥7.26 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥38.02 Billion |
|
Shanghai Junshi Biosciences Co Ltd
SHG:688180
|
China | CN¥11.69 Billion |
|
Spyre Therapeutics Inc.
NASDAQ:SYRE
|
USA | $504.60 Million |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $563.83 Million |
Abpro Holdings, Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.07 | 0.17 | 0.19 |
| Quick Ratio | 0.07 | 0.17 | 0.19 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-16.07 Million | $-7.48 Million | $-4.46 Million |
Abpro Holdings, Inc. - Advanced Valuation Insights
This section examines the relationship between Abpro Holdings, Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 0.43 |
| Asset Growth Rate (YoY) | 38.9% |
| Total Assets | $4.66 Million |
| Market Capitalization | $2.00 Million USD |
Valuation Analysis
Below Book Valuation: The market values Abpro Holdings, Inc.'s assets below their book value (0.43x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Abpro Holdings, Inc.'s assets grew by 38.9% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Abpro Holdings, Inc. (2016–2024)
The table below shows the annual total assets of Abpro Holdings, Inc. from 2016 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $4.66 Million | +38.93% |
| 2023-12-31 | $3.35 Million | -71.69% |
| 2022-12-31 | $11.85 Million | +50.25% |
| 2021-12-31 | $7.89 Million | -53.98% |
| 2017-12-31 | $17.14 Million | +122.93% |
| 2016-12-31 | $7.69 Million | -- |
About Abpro Holdings, Inc.
Abpro Holdings, Inc., a biotechnology company, focuses on novel antibody constructs for immuno-oncology and ophthalmology. Its platforms include DiversImmune, a discovery platform that generates a diverse collection of proprietary antibodies against clinically validated and novel targets; and MultiMab, an engineering platform that provides the flexibility to combine antibody building blocks in di… Read more